CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-07-09): Demographic variations seen in liver cancer incidence in US

Epidemiology

Demographic variations seen in liver cancer incidence in US

Last Updated: 2008-07-09 15:19:37 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The incidence of hepatocellular carcinoma in the US differs significantly by sex, ethnicity, and age at diagnosis, according to results of a study published in the June issue of the American Journal of Medicine.

"The increasing incidence of hepatocellular carcinoma coupled with this cancer's high mortality is a public health problem," write Dr. Robert Wong, of the University of California, San Francisco, and colleagues. "Current clinical guidelines recommend initiating hepatocellular carcinoma screening in some high-risk groups, but little data are available in the United States regarding how cancer incidence may differ by age and race/ethnicity."

The team used data from the Surveillance, Epidemiology, and End Results program, a population-based cancer registry, to examine the age-specific, sex-specific, and race-specific variability of hepatocellular carcinoma incidence from 1992 to 2004.

A total of 18,442 cases of hepatocellular carcinoma were identified. When males and females were combined, the team found that Asians had nearly twice the incidence rate of white Hispanics (11.0 versus 6.8 per 100,000/y; p < 0.0001) and more than four times that of Caucasians (11.0 versus 2.6 per 100,000/y; p < 0.0001).

Males had a doubling of cancer rates every 10 years from 30 to 50 years of age, according to the authors. "Females reached male-comparable rates of cancer 10 to 15 years later, and they peaked at significantly lower values for all race/ethnic groups," the team found.

"The possibility that groups with similar identifiable risk factors can present with significantly different disease risk suggests that, if screening is effective, an individualized approach may more efficiently identify treatable tumors than more general guidelines, while minimizing interventions on patients with relatively lower risks of progressing to cancer," Dr. Wong's team concludes.

They add, "More studies are needed to determine disease-specific variations in cancer risks (e.g., hepatitis B and C) and whether incorporating the variations observed into surveillance protocols is clinically efficacious."

Am J Med 2008-121:525-531.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.